Delcath grants options and RSUs to Kevin Muir
Delcath Systems, Inc. granted equity awards to Kevin Muir, its GM Interventional Oncology.
Rhea-AI Filing Summary
Delcath Systems, Inc. granted equity awards to Kevin Muir, its GM Interventional Oncology. On February 17, 2026, he acquired a stock option covering 56,500 shares at an exercise price of $0.00 per share, vesting in equal monthly installments over 36 months, starting February 17, 2026, while he remains an employee and subject to the company’s 2020 Omnibus Equity Incentive Plan.
On the same date, he also received 28,250 restricted stock units (RSUs), each representing a contingent right to one share of common stock. One-third of this RSU award will vest on February 17, 2027, with the remaining two-thirds vesting in equal annual installments over the following two years, subject to his continuous service through each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 56,500 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units | 28,250 | $0.00 | $0.00 |
Footnotes (3)
- F1. The option will vest and become exercisable at the rate of one-thirty-sixth (1/36th) per month with the first such vesting to occur on February 17, 2026 and monthly thereafter for so long as the reporting person remains an employee of Delcath Systems, Inc. (and subject to the terms and conditions of the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended).
- F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.
- F3. Represents an RSU award, one-third of which shall vest on February 17, 2027 with the remaining 2/3 two-thirds of the RSUs vesting in equal annual installments over the following two years. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.